United States: Florida Enacts Law To Implement Provisions Of Its Medical Marijuana Amendment, But Significant Questions Remain For Employers

Executive Summary: Late last week Florida Governor Rick Scott signed into law a bill intended to implement provisions of the medical marijuana constitutional amendment that was approved by Florida voters last November (Amendment 2). The new law addresses and preserves important employer rights regarding drug-free workplace policies generally, but it leaves unanswered a number of significant questions that may ultimately end up needing to be resolved by courts. Although the new law expressly provides that it does not create a private cause of action against employers for wrongful discharge or discrimination, and does not require an employer to accommodate the use of medical marijuana at work, it does not squarely address the extent of an employer's obligation to accommodate the use of medical marijuana outside the workplace. Thus far cases decided in other states with similar medical marijuana statutes or constitutional amendments have upheld an employer's right to continue to apply uniform "zero tolerance" drug free workplace policies that prohibit the use of marijuana under any circumstances at any time. While these court decisions in other jurisdictions should provide Florida employers some comfort, how a Florida court would resolve a similar legal challenge remains to be seen, particularly in a case that also implicates the Americans with Disabilities Act (ADA), the Florida Civil Rights Act (FCRA) and/or the Family and Medical Leave Act (FMLA).

Signing of Florida Senate Bill 8-A into Law and Evolution of Medical Marijuana in Florida

On June 23, 2017, Governor Rick Scott signed into law Senate Bill 8-A, which implemented Amendment 2, the "Florida Medical Marijuana Legislation Initiative." Amendment 2 followed the enactment of Senate Bill 1030 in 2014, which created the "Compassionate Medical Cannabis Act of 2014," now codified as Florida Statute §381.986. Among other things, §381.986 originally legalized low-THC cannabis for medical use by qualified patients who suffered from cancer or certain conditions that caused chronic seizures or severe and persistent muscle spasms.

Consistent with Amendment 2, the new law amends §381.986 to provide for the medical use of stronger strains of marijuana, although it excludes, somewhat controversially, marijuana in forms used for smoking (other than for vaping). It also significantly expands the numbers and kinds of "debilitating medical conditions" for which medical marijuana legally may be used, including cancer, epilepsy, glaucoma, the human immunodeficiency virus (HIV), acquired immune deficiency syndrome (AIDS), post-traumatic stress disorder (PTSD), amyotrophic lateral sclerosis (ALS), Crohn's disease, Parkinson's disease, and multiple sclerosis. The law also provides for a "catch-all" category for other conditions "of the same kind or class as or comparable" to those enumerated, if a physician believes that the medical use of marijuana would "likely outweigh the potential health risks for the patient."

In addition, the new law also incorporates a provision into §381.986 that provides limited guidance on the legal impact of medical marijuana on the workplace, including providing that the law does not limit the ability of an employer in Florida to maintain a drug-free workplace program or policy, or provide a basis for individuals to bring claims of wrongful discharge or discrimination against an employer. Specifically, Subsection 15 of the new law provides:

Applicability.— This section does not limit the ability of an employer to establish, continue, or enforce a drug-free workplace program or policy. This section does not require an employer to accommodate the medical use of marijuana in any workplace or any employee working while under the influence of marijuana. This section does not create a cause of action against an employer for wrongful discharge or discrimination. Marijuana, as defined in this section, is not reimbursable under chapter 440 [the "Workers' Compensation Law"].

The Law Does Not Address an Employers' Potential Duty to Accommodate Medical Marijuana Use Off-Site or other Possible ADA/FCRA/FMLA Concerns

FordHarrison first analyzed the likely impact of the legalization of medical marijuana on Florida employers not long after the passage of Amendment 2, in our Alert " What Does Florida's New Medical Marijuana Law Mean for Employers?" As noted in that Alert, the language of the amendment made clear that employers would not have an obligation to accommodate any on-site use of medical marijuana in the workplace as a result of the amendment's passage. Similarly, as noted above, Subsection 15 of amended §381.986 expressly denies any duty to accommodate the use of medical marijuana in the workplace or an individual working while under the influence of medical marijuana. However, like Amendment 2, amended §381.986 does not expressly address whether employers may have to accommodate medical marijuana use by applicants or employees outside of the workplace, including as a result of any accommodation obligations arising under the ADA or FCRA.

While no Florida courts have yet had occasion to address this issue, in other jurisdictions with medical marijuana laws that are silent on the issue of accommodation of the use of medical marijuana outside of work, courts have consistently upheld an employer's right to observe and enforce uniformly applied "zero tolerance" drug free workplace policies against applicants or employees who failed drug tests as a result of the use of medical marijuana. For example, in Roe v. TeleTech Customer Care Management (Colorado) LLC, 257 P.3d 586 (Wash. 2011), a medical marijuana user in Washington State sued her former employer for wrongful termination based on a "new hire" positive drug test. The plaintiff argued, among other things, that the legislature's express denunciation of an employers' duty to accommodate "any on-site medical use of marijuana in any place of employment" impliedly created a duty to accommodate such use off-site. The Washington Supreme Court disagreed, finding that "the statute's explicit statement against an obligation to accommodate on-site use [did] not require reading into [the law] an implicit obligation to accommodate off-site medical marijuana use." Should amended §381.986 face a similar challenge in the future, Florida courts may similarly decline to read into the statute an unexpressed obligation to accommodate off-site use, particularly in light of the statute's express language stating it does not create a cause of action for wrongful discharge.

In our earlier Alert we also observed that because marijuana remains illegal under federal law, a user of medical marijuana seemingly would not satisfy the definition of a "qualified individual with a disability" under the ADA, as the ADA expressly excludes from coverage any employee or job applicant "who is currently engaging in the illegal use of drugs, when the [employer] acts on the basis of such use." 42 U.S.C. §12114a. (The ADA in turn defines "illegal drugs" by reference to federal law (under the federal Controlled Substances Act), not state law.). Although courts generally have construed the FCRA in conformity with the ADA in most circumstances, the answer could be less clear under the FCRA, which has no analogous express provision tied to use of drugs that are illegal under federal law.

Employers must also keep in mind, however, that even though the ADA does not protect current use of medical marijuana or actions taken because of its use (such as terminations under a zero tolerance policy), the underlying condition (and/or disclosure of it to the employer) may still implicate and impose ADA and FCRA obligations, including an obligation to engage in the ADA interactive process with the employee and/or explore other accommodations independent of the use of medical marijuana. Similarly, the underlying condition for which medical marijuana is being used will likely be considered a "serious health condition" under the FMLA, in turn triggering certain rights for the eligible employee to take protected leaves of absence from work. Thus, employers need to consider the possible applicability of the FMLA when addressing an employee's use of medical marijuana.

It remains to be seen how courts will interpret the provision in the new law that states the statute does not create a cause of action for wrongful discharge or discrimination when that provision is applied in a specific workplace scenario. Seemingly, so long as an employer can show that its employment decision is based solely upon an individual's use of marijuana, and not on the medically authorized reason for the use, the provision in Subsection 15 would appear to provide a basis for arguing that any such lawsuit is barred by the statute. Again, however, only time will tell as this point.

Employers' Bottom Line: Although amended §381.986 contains seemingly employer-friendly provisions, Florida employers still need to be cautious and aware in the coming weeks and months of open issues not addressed or clarified in the new law. For now, employers should review their current policies and practices to be sure they account for the fact that marijuana is treated differently under federal and state law, remain vigilant in monitoring developments in this area of the law, and consult with qualified legal counsel when encountering situations implicating the ADA, FCRA or FMLA and the authorized medical use of marijuana.

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement

Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of www.mondaq.com

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at enquiries@mondaq.com.

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.